Jubilant Life Sciences, an integrated pharma and life sciences company, announced today that Gurpartap Sing Sachdeva has been appointed as CEO of Jubilant pharma, a 100% wholly-owned subsidiary of JLL.
Singh will have overall responsibility for the operations under Jubilant Pharma and will report to the Jubilant Pharma board. He will be based in the United States.
Prior to Jubilant, Singh had served as president of Sun Pharmaceuticals, USA and contributed to the growth of Sun's US in various leadership roles pertaining to strategy, M&A, commercial and operations.
Shares of the company gained Rs 5.15, or 3.69%, to settle at Rs 144.85. The total volume of shares traded was 445,625 at the BSE (Tuesday).